Atossa Genetics Inc (NASDAQ:ATOS) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 1,002,202 shares, an increase of 42.3% from the August 31st total of 704,353 shares. Currently, 8.8% of the shares of the company are sold short. Based on an average trading volume of 4,190,944 shares, the days-to-cover ratio is presently 0.2 days.

Shares of Atossa Genetics (ATOS) opened at 0.5298 on Thursday. Atossa Genetics has a 52-week low of $0.32 and a 52-week high of $2.60. The company has a 50-day moving average price of $0.49 and a 200 day moving average price of $0.55. The firm’s market capitalization is $6.20 million.

Atossa Genetics (NASDAQ:ATOS) last posted its earnings results on Monday, August 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.20). Analysts expect that Atossa Genetics will post ($3.57) EPS for the current fiscal year.

A hedge fund recently bought a new stake in Atossa Genetics stock. Sabby Management LLC acquired a new position in Atossa Genetics Inc (NASDAQ:ATOS) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 291,046 shares of the company’s stock, valued at approximately $150,000. Sabby Management LLC owned about 2.49% of Atossa Genetics at the end of the most recent reporting period. Institutional investors own 7.95% of the company’s stock.

WARNING: “Short Interest in Atossa Genetics Inc (ATOS) Rises By 42.3%” was first published by Marea Informative and is the property of of Marea Informative. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at

About Atossa Genetics

Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.

Receive News & Stock Ratings for Atossa Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc and related stocks with our FREE daily email newsletter.